(Q45187271)
Statements
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study (English)
J-Y Douillard
R Gervais
G Dabouis
A Le Groumellec
M D'Arlhac
D Spaeth
D Caillaud
A Monnier
C Clary
B Maury
M Mornet
A Rivière
P Clouet